Akoya Biosciences acquires Phenoptics portfolio from PerkinElmer
Akoya Biosciences, a Telegraph Hill Partners (THP) company, has acquired PerkinElmer, Inc.’s Phenoptics portfolio. Akoya was founded in 2015 to commercialize the CODEX multiparameter tissue analysis technology developed in the lab of Dr Garry Nolan at Stanford University. PerkinElmer has grown its Phenoptics business, to be an industry leader in multiplex immunofluorescence. This acquisition establishes Akoya as a leading provider of quantitative tissue biomarker evaluation, from discovery through translational and clinical research. High-parameter analysis of biological tissue samples provides critical spatial context in studies of autoimmune disease, immune-oncology and many other research areas. The Phenoptics portfolio, with its Mantra, Vectra and Vectra Polaris systems, provides the throughput and standardization required to support largescale translational studies. Its multispectral imaging instruments, reagents, software and research services have been adopted by hundreds of labs globally. CODEX enables biomarker discovery with detection of up to 50 markers on a single tissue section with reagents and instrumentation that integrate with our customer’s existing microscopes. CODEX includes optimized assay reagents combined with validated antibodies labeled with proprietary CODEX Barcodes to enable a simple, automated workflow.